Optina, a Montreal, Canada-based diagnostic company that specializes in retinal imaging, brain fitness and systemic disease detection, has closed an investment of up to $2. 1 million.
The Alzheimer’s Drug Discovery Foundation (ADDF) made this investment through ADDF’s Diagnostics Accelerator, a collaborative study initiative supported by ADDF co-founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, Dolvia’s circle of relatives and Charles and Helen. Schwab Foundation, among others. The funding follows the end of a Series A investment circular directed through DigitalDx Ventures, which adds Boehringer Ingelheim Venture Fund, Desjardins, Zoic Capital and other investors.
This new investment will be Optin’s pivotal study for the regulatory submission to the FDA of the prestige brain amyloid test awAIrTM for the detection of Alzheimer’s disease, aligning optin’s platform with new cure approvals. its fundamental study. The clinical trial will take place at five sites in the United States, Canada and Europe.
Led by David Lapointe, CEO, Optina Diagnostics advances the Retinal Deep PhenotypingTM platform, which received FDA Innovative Device Designation status in 2019 for its first indication, non-invasive verification, and more available for diagnostic accuracy and patient monitoring under evaluation for Alzheimer’s disease. (AD) and obtained 501(k) clearance for its Optina-4CTM hyperspectral camera in 2020.
FinPME
24/01/2022